Business
Kalytera Announces Results of Shareholder Meeting Votes
Kalytera Announces Results of Shareholder Meeting Votes.
About this update from Claritas Pharmaceuticals Inc.
[{"type":"text","content":"\nSAN FRANCISCO and TEL AVIV, Israel, July 29, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that shareholder votes on the election of directors, the approval of the Company’s auditors and the renewal of its Stock Option Plan were approved by the Company’s shareholders.\n The Company did not proceed with the shareholder vote with respect to the authorization of a potential share consolidation. Kalytera will therefore proceed accordingly with initiatives that are already under discussion.  Additional information regarding the Shareholder Meeting can be found in the Circular dated June 21, 2019, which was delivered to Kalytera shareholders and is available on the Company’s SEDAR profile. About Kalytera Therapeutics Kalytera Therapeutics, Inc. is pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on graft versus host disease and the treatment of acute and chronic pain. Website Home: https://kalytera.co/  News and Insights: https://kalytera.co/news/ Investors: https://kalytera.co/investors/ Cautionary Statements Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release may contain certain forward-looking information and statements (“forward-looking information”) within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation in respect of its product candidate pipeline, planned clinical trials, regulatory approval prospects, intellectual property objectives and other statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Readers ...